Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00683722
Other study ID # 801
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 20, 2008
Est. completion date August 24, 2010

Study information

Verified date December 2021
Source Mesoblast, Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the present study is to establish the safety and efficacy of multiple administrations of Prochymal™(ex-vivo cultured human adult mesenchymal stem cells) in participants with moderate to severe chronic obstructive pulmonary disease (COPD).


Description:

COPD is currently the fourth leading cause of death in the United States. It is clear that there is a significant unmet medical need for safe and effective therapies to treat moderate to severe COPD. This patient population has a high mortality rate and requires frequent hospitalizations due to disease-related exacerbations. Based on severity distribution estimates, approximately 70% of all current COPD patient have either moderate or severe COPD. COPD has no known cure, thus current therapeutic intervention is aimed at providing relief of symptoms. Oxygen therapy is the only treatment that has been shown to improve survival. Smoking cessation has been shown to slow the rate of forced expiratory volume in 1 second (FEV1) decline and COPD progression. In general patient are treated with bronchodilators and inhaled corticosteroids, but again, these measures do not provide any significant benefit regarding disease progression or prognosis. The characteristics and biologic activity of Prochymal™, along with a good safety profile in human trials to date, suggest that Prochymal™ may be a good candidate for addressing this unmet medical need.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date August 24, 2010
Est. primary completion date March 9, 2009
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: - Participant must have a diagnosis of moderate or severe COPD. - Participant must have a post-bronchodilator FEV1/forced vital capacity (FVC) ratio < 0.7. - Participant must have a post-bronchodilator FEV1 % predicted value = 30% and < 70%. - Participant must be between 40 and 80 years of age, of either sex, and of any race. - Participant must be a current or ex-smoker, with a cigarette smoking history of = 10 years or > 10 pack-years. Exclusion Criteria: - Participant has been diagnosed with asthma or other clinically relevant lung disease other than COPD (e.g. restrictive lung diseases, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, bronchiectasis, or lung cancer). - Participant has been diagnosed with a1-antitrypsin deficiency. - Participant has a body mass greater than 150 kg (330 lb) or less than 40 kg (88 lb). - Participant has active infection. - Participant has had a significant exacerbation of COPD or has required mechanical ventilation within 4 weeks of screening. - The participant with clinically relevant uncontrolled medical condition not associated with COPD. - Participant has documented history of uncontrolled heart failure. - Participant has pulmonary hypertension due to left heart condition. - Participant has atrial fibrillation or significant congenital heart defect/disease. - Participant has initiated pulmonary rehabilitation within 3 months of screening. - Participant is allergic to bovine or porcine products. - Participant has evidence of active malignancy, or prior history of active malignancy that has not been in remission for at least 5 years. - Participant has a life expectancy of < 6 months.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Prochymal™
IV infusion of ex- vivo cultured adult human mesenchymal stem cells.
Placebo
IV infusion of excipient of Prochymal™.

Locations

Country Name City State
United States Vermont Lung Center, University of Vermont Burlington Vermont
United States American Health Research Charlotte North Carolina
United States Upstate Pharmaceutical Research Greenville South Carolina
United States David Geffen School of Medicine at UCLA Los Angeles California
United States Spartanburg Medical Research Spartanburg South Carolina
United States Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center Torrance California

Sponsors (1)

Lead Sponsor Collaborator
Mesoblast, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Adverse Events (AEs) Up to 2 Years
Secondary Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume (FEV)1 at Year 1 and Year 2 Baseline, Year 1, Year 2
Secondary Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume (FEV)1 %predicted at Year 1 and Year 2 Baseline, Year 1, Year 2
Secondary Change from Baseline in Pulmonary Function Test: Forced Vital Capacity (FVC) at Year 1 and Year 2 Baseline, Year 1, Year 2
Secondary Change from Baseline in Pulmonary Function Test: Forced Vital Capacity (FVC) %predicted at Year 1 and Year 2 Baseline, Year 1, Year 2
Secondary Change from Baseline in Pulmonary Function Test: Forced Expiratory Volume to Forced Vital Capacity Ratio (FEV1/FVC) at Year 1 and Year 2 Baseline, Year 1, Year 2
Secondary Change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) at Year 1 and Year 2 Baseline, Year 1, Year 2
Secondary Change from Baseline in Diffusing capacity of the lung for carbon monoxide (DLCO) %predicted at Year 1 and Year 2 Baseline, Year 1, Year 2
Secondary Change from Baseline in Alveolar Volume (VA) at Year 1 and Year 2 Baseline, Year 1, Year 2
Secondary Change from Baseline in Diffusing capacity of the lung for carbon monoxide to Alveolar Volume ratio (DLCO/VA)at Year 1 and Year 2 Baseline, Year 1, Year 2
Secondary Change from Baseline in Functional residual capacity (FRC) at Month 6 Baseline, Month 6
Secondary Change from Baseline in Total Lung Capacity (TLC) at Month 6 Baseline, Month 6
Secondary Change from Baseline in Residual Volume (RV) at Month 6 Baseline, Month 6
Secondary Change from Baseline in Airway Resistance (RAW) at Month 6 Baseline, Month 6
Secondary Change from Baseline in 6-Minute Walk Test at Year 1 and Year 2 Change from baseline in the total distance walked in 6 minutes was reported. Baseline, Year 1, Year 2
Secondary Change from Baseline in Borg Dyspnea Scale at Year 2 Baseline, Year 2
Secondary Change from Baseline in Health-related quality of life: St George's Respiratory Questionnaire (SGRQ) at Year 1 and Year 2 Baseline, Year 1, Year 2
Secondary Change from Baseline in Physician Global Assessment Scale at Year 1 and Year 2 The physician evaluated the subject's global status as improved, unchanged, or worsened from pretreatment. Baseline, Year 1, Year 2
Secondary Time to COPD Exacerbation Up to 2 Years
Secondary Number of COPD Exacerbations Up to 2 Years
Secondary Change from Baseline in Pulmonary Hypertension at Month 6 Baseline, Month 6
Secondary Change from Baseline in Systemic Inflammation at Year 1 and Year 2 Changes in systemic inflammation was determined by C-Reactive Protein (CRP) assays. Baseline, Year 1 and Year 2
See also
  Status Clinical Trial Phase
Completed NCT05043428 - The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD N/A
Completed NCT00528996 - An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler. Phase 2
Completed NCT03740373 - A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate Phase 1
Completed NCT05402020 - Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
Completed NCT05393245 - Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
Completed NCT04011735 - Re-usable Respimat® Soft MistTM Inhaler Study
Enrolling by invitation NCT03075709 - The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
Completed NCT03764163 - Image and Model Based Analysis of Lung Disease Early Phase 1
Completed NCT00515268 - Endotoxin Challenge Study For Healthy Men and Women Phase 1
Completed NCT04085302 - TARA Working Prototype Engagement Evaluation: Feasibility Study N/A
Completed NCT03691324 - Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study N/A
Completed NCT02236611 - A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT00153075 - Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT01017952 - A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT01009463 - A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT04882124 - Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD Phase 2
Completed NCT02853123 - Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients Phase 4
Completed NCT02619357 - Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma Phase 1
Recruiting NCT05858463 - High Intensity Interval Training and Muscle Adaptations During PR N/A
Not yet recruiting NCT05032898 - Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II